Infliximab induces clinical, endoscopic and histological responses in refractory ulcerative colitis;Infliximab induce respuesta clínica, endoscópica e histológica en la colitis ulcerosa refractaria

Revista Espanola de Enfermedades Digestivas

Volumn 96, Issue 2, 2004, Pages 94-101

  Bermejo, Fernando ^c,d   Lopez Sanroman A ^c   Hinojosa, J ^a   Castro, L ^b   Jurado, C ^b   Gomez Belda A B ^a  

^a HOSPITAL DE SAGUNTO   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d NONE   (Spain)

Author keywords

Infliximab; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; BUDESONIDE; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; MONOCLONAL ANTIBODY; PREDNISOLONE; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL FEATURE; COLONOSCOPY; CROHN DISEASE; DISEASE ACTIVITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; ERYTHROCYTE SEDIMENTATION RATE; EXPERIENCE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MEDICAL ASSESSMENT; SIDE EFFECT; SPAIN; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 1642526533     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/S1130-01082004000200002     Document Type: Article

References (32)

1. Hinojosa J. Anticuerpos anti-TNF en el tratamiento de la enfermedad inflamatoria intestinal. Gastroenterol Hepatol 2000; 23: 250-7.
2. Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterol 2002; 122: 1592-608.
3. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
4. Present DH, Rutgeerts P, Targan SR, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-405.
5. Domenech E, Esteve-Comas M, Gomollón F, Hinojosa J, Obrador A, Panés J, et al. Recomendaciones para el uso de infliximab (Remicade®) en la enfermedad de Crohn. GETECCU 2001. Gastroenterol Hepatol 2002; 25: 162-8.
6. Caprilli R, Viscido, A, Guagnozzi D. Review article: biological agents in the treatment of Crohn's disease. Aliment Pharmacol Ther 2002; 16: 1579-90.
7. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989; 170: S2-S6.
8. O'Morain C, Tobin A, Leen E, Suzuki Y, O'Riordan T. Criteria of case definition in Crohn's disease and ulcerative colitis. Scand J Gastroenterol 1989; 170: S7-S11.
9. Lichtiger SC, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporin in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841-5.
10. Faubion WA, Loftus EV, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study. Gastroenterology 2001; 121: 255-60.
11. Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut 1988; 29: 669-74.
12. Obrador A, López San Román A, Muñoz P, Fortun J, Gassull MA. Guía de consenso sobre tuberculosis y tratamiento de la enfermedad inflamatoria intestinal con infliximab. Gastroenterol Hepatol 2003; 26: 29-33.
13. Lichtenstein GR. Is Infliximab effective for induction of remission in patients with ulcerative colitis? Infl Bowel Dis 2001; 7: 89-93.
14. Fiocchi C. Inflammatory bowel disease: Etiology and pathogenesis. Gastroenterology 1998; 115: 182-205.
15. Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993; 94: 174-81.
16. Masuda H, Iwai S, Tanaka T, Hayakawa S. Expression of IL-8, TNF-alpha and IFN-gamma m-RNA in ulcerative colitis, particularly in patients with inactive phase. J Clin Lab Immunol 1995; 46: 111-23.
17. Reimund JM, Wittersheim C, Dumont S, Muller CD, Baumann R, Poindron P, et al. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol 1996; 16: 144-50.
18. Nielsen OH, Gionchetti P, Ainsworth M, Vainer B, Campieri M, Borregaard N, et al. Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-alpha in ulcerative colitis. Am J Gastroenterol 1999; 94: 2923-8.
19. Saiki T, Mitsuyama K, Toyonaga A, Ishida H, Tanikawa K. Detection of pro- and anti-inflammatory cytokines in stools of patients with inflammatory bowel disease. Scand J Gastroenterol 1998; 33: 616-22.
20. Hadziselimovic F, Emmons LR, Gallati H. Soluble tumour necrosis factor receptors p55 and p75 in the urine monitor disease activity and the efficacy of treatment of inflammatory bowel disease. Gut 1995; 37: 260-3.
21. Evans RC, Clarke L, Heath P, Stephens S, Morris AI, Rhodes JM. Treatment of ulcerative colitis with an engineered anti-TNF alpha antibody CDP 571. Aliment Pharmacol Ther 1997; 11: 1031-5.
22. Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, et al. Infliximab in the treatment of severe steroid-refractory ulcerative colitis: A pilot study. Infl Bowel Dis 2001; 7: 83-8.
23. Chey WY, Hussain A, Ryan C, Potter GD, Shah A. Infliximab for refractory ulcerative colitis. Am J Gastroentrol 2001; 96: 2373-81.
24. Kaser A, Mairinger T, Vogel W, Tilg H. Infliximab in severe steroid-refractory ulcerative colitis: A pilot study. Wien Klin Wochenschr 2001; 113: 930-3.
25. Su C, Salzberg BA, Lewis JD, Deren J, Kornbluth A, Katzka DA, et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002; 97: 2576-84.
26. Kohn A, Prantera C, Pera A, Cosintino R, Sostegni R, Daperno M. Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: Result of an open study on 13 patients. Dig Liver Dis 2002; 34: 626-30.
27. Actis GC, Bruno M, Pinna-Pintor M, Rossini FP, Rizzetto M. Infliximab for treatment of steroid-refractory ulcerative colitis. Dig Liver Dis 2002; 34: 631-4.
28. Castro Fernández M, García Díaz E, Romero M, Galán Jurado V, Rodriguez Alonso C. Tratamiento de la colitis ulcerosa corticorrefractaria con infliximab. Gastroenterol Hepatol 2003; 26: 54-5.
29. Probert CSJ, Hearing SD, Schreiber S, Kühbacher T, Ghosh S, Arnott IDR, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: A randomised controlled trial. Gut 2003; 52: 998-1002.
30. Gornet JM, Couve S, Hassani Z, Delchier JC, Marteau P, Cosnes J, et al. Infliximab for refractory ulcerative colitis or indeterminate colitis: An open-label multicentre study. Aliment Pharmacol Ther 2003; 18: 175-81.
31. Kugathasan S, Prajapati DN, Kim JP, Saeian K, Emmons J, Knox J, et al. Infliximab outcome in children and adults with ulcerative colitis. Gastroenterology 2002; 122: A-615.
32. Binderow SR, Wexner SD. Current surgical therapy for mucosal ulcerative colitis. Dis Colon Rectum 1994; 37: 610-24.